SCHEMBL4717951

SCHEMBL4717951

Clc1cc(Nc2cccc3cnccc23)ncn1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.45
SMN1; SMN2 Q16637 4/20 0.45
LMNA P02545 3/20 0.45
HPGD P15428 2/20 0.45
HTT P42858 2/20 0.45
TP53 P04637 1/20 0.45
POLB P06746 1/20 0.45
PKM P14618 1/20 0.45
BLM P54132 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
TRPV1 Q8NER1 7/20 0.44
MAPT P10636 6/20 0.44
KDM4E B2RXH2 5/20 0.44
CASP3 P42574 1/20 0.44
SENP8 Q96LD8 1/20 0.44
SENP7 Q9BQF6 1/20 0.44
SENP6 Q9GZR1 1/20 0.44
CCR4 P51679 1/20 0.43
ROCK2 O75116 4/20 0.43
ROCK1 Q13464 3/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4716401 0.83 TRPV1 (0.48) ALDH1A1SMN1; SMN2LMNAHPGDHTT
SCHEMBL4717106 0.83 TRPV1 (0.43) ALDH1A1SMN1; SMN2LMNAHPGDHTT
SCHEMBL4716052 0.81 PDE4B (0.51) ALDH1A1SMN1; SMN2HTTTP53BLM
SCHEMBL4716399 0.80 KDR (0.47) ALDH1A1TRPV1CCR4
SCHEMBL15452589 0.79 CDK2 (0.50) ALDH1A1SMN1; SMN2LMNAHPGDHTT
SCHEMBL4718692 0.79 TRPV1 (0.49) ALDH1A1TP53TRPV1MAPTKDM4E
SCHEMBL4718504 0.78 TRPV1 (0.59) ALDH1A1SMN1; SMN2LMNAHPGDHTT
SCHEMBL4719637 0.78 TRPV1 (0.48) ALDH1A1SMN1; SMN2TRPV1MAPTKDM4E
SCHEMBL4715734 0.77 TRPV1 (0.45) ALDH1A1HTTBLMTRPV1MAPT
SCHEMBL4718686 0.77 ALDH1A1 (0.48) ALDH1A1SMN1; SMN2HPGDTRPV1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7442701-B2 Amino-heterocycles as VR-1 antagonists for treating pain MERCK SHARP & DOHME LTD. (GB) 2008-10-28 US disclosed
EP-1562934-B1 AMINO-HETEROCYCLES AS VR-1 ANTAGONISTS FOR TREATING PAIN MERCK SHARP & DOHME (GB) 2008-03-26 EP disclosed
US-20060040947-A1 Amino-heterocycles as vr-1 antagonists for treating pain MERCK SHARP & DOHME LTD. (GB) 2006-02-23 US disclosed
EP-1562934-A1 AMINO-HETEROCYCLES AS VR-1 ANTAGONISTS FOR TREATING PAIN MERCK SHARP & DOHME LTD. (GB) 2005-08-17 EP disclosed
WO-2004046133-A1 AMINO-HETEROCYCLES AS VR-1 ANTAGONISTS FOR TREATING PAIN MERCK SHARP & DOHME LIMITED (GB) 2004-06-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060040947-A1 Amino-heterocycles as vr-1 antagonists for treating pain OPRL1, CNR1, GPR6 ALDH1A1 2473/4885SMN1; SMN2 2309/4885LMNA 4537/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.